Cancers, 2020-03, Vol.12 (3), p.687
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
- Ist Teil von
- Cancers, 2020-03, Vol.12 (3), p.687
- Ort / Verlag
- Switzerland: MDPI AG
- Erscheinungsjahr
- 2020
- Quelle
- EZB Free E-Journals
- Beschreibungen/Notizen
- Poly-ADP ribose polymerase (PARP) inhibitors are currently used in the treatment of several cancers carrying mutations in the breast and ovarian cancer susceptibility genes and , with many more potential applications under study and in clinical trials. Here, we discuss the potential for extending PARP inhibitor therapies to tumours with deficiencies in the DNA damage-activated protein kinase, Ataxia-Telangiectasia Mutated (ATM). We highlight our recent findings that PARP inhibition alone is cytostatic but not cytotoxic in ATM-deficient cancer cells and that the combination of a PARP inhibitor with an ATR (ATM, Rad3-related) inhibitor is required to induce cell death.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2072-6694eISSN: 2072-6694DOI: 10.3390/cancers12030687Titel-ID: cdi_doaj_primary_oai_doaj_org_article_a9c064e50c564fcc891dc9fca9dc689f
- Format
- –
- Schlagworte
- Ataxia, atm, atr, BRCA1 protein, BRCA2 protein, Breast cancer, Cancer therapies, Cell cycle, Cell death, Clinical trials, Colorectal cancer, Cytotoxicity, Defects, Deoxyribonucleic acid, DNA, DNA damage, DNA repair, Genomes, Kinases, Lung cancer, Lymphoma, Mutation, olaparib, Oncology, Ovarian cancer, Pancreatic cancer, parp, parp inhibitor, Poly(ADP-ribose) polymerase, Precision medicine, Prostate, prostate cancer, Protein kinase, Proteins, Regulatory approval, Review, Ribose, Roles, Tumors